Interstitial Pneumonitis after Treatment with Pemetrexed for Non-small Cell Lung Cancer
Cancer Research and Treatment 2013³â 45±Ç 1È£ p.74 ~ p.77
±è°æÇö(Kim Kyeong-Hyun) - Kangwon National University School of Medicine Kangwon National University Hospital Department of Internal Medicine
¼Û¼¼¿µ(Song Seo-Young) - Kangwon National University School of Medicine Kangwon National University Hospital Department of Internal Medicine
ÀÓ±ÔÇü(Lim Kyu-Hyoung) - Kangwon National University School of Medicine Kangwon National University Hospital Department of Internal Medicine
ÇѼ±¼÷(Han Seon-Sook) - Kangwon National University School of Medicine Kangwon National University Hospital Department of Internal Medicine
±è¼¼Çö(Kim Se-Hyun) - Kangwon National University School of Medicine Kangwon National University Hospital Department of Internal Medicine
Á¶ÁØÈÖ(Cho Jun-Hwi) - Kangwon National University School of Medicine Kangwon National University Hospital Department of Emergency Medicine
¹ÚÂù¿ì(Park Chan-Woo) - Kangwon National University School of Medicine Kangwon National University Hospital Department of Emergency Medicine
(Lee Seoung-Koo) - Kangwon National University School of Medicine Kangwon National University Hospital Department of Pathology
ÀÌÈñ¿µ(Lee Hui-Young) - Kangwon National University School of Medicine Kangwon National University Hospital Department of Internal Medicine
Abstract
Pemetrexed is approved as a first-line treatment for advanced non-squamous non-small cell lung cancer (NSCLC) with cisplatin and as a single agent for second-line treatment or for patients who show no disease progression after four cycles of platinum-based doublet induction chemotherapy as maintenance therapy. Pemetrexed has a modest toxicity profile and has not traditionally been regarded as a cause of interstitial pneumonitis. Here, we report on a rare case of pemetrexed-induced pneumonitis in a patient with NSCLC.
Å°¿öµå
Interstitial lung diseases, Pemetrexed, Non-small-cell lung carcinoma, Adenocarcinoma, Drug therapy
KMID :
0939920130450010074
¿ø¹® ¹× ¸µÅ©¾Æ¿ô Á¤º¸
µîÀçÀú³Î Á¤º¸
À¯È¿¼º°á°ú(Recomendation)
A rare case of pemetrexedinduced pneumonitis in a patient with NSCLC. Pemetrexed is approved as a first-line treatment for advanced non-squamous non-small cell lung cancer (NSCLC) with cisplatin and as a single agent for second-line treatment or for patients who show no disease progression after four cycles of platinum-based doublet induction chemotherapy as maintenance therapy. Pemetrexed has a modest toxicity profile and has not traditionally been regarded as a cause of interstitial pneumonitis. This study reports on a rare case of pemetrexed-induced pneumonitis in a patient with NSCLC.